Noxxon Pharma, AG: Series D $40M

Posted in I - Series D, Q - 2Q10, R - INTERNATIONAL, X - Aptamer, X - Hematology, X - Inflammation

Noxxon Pharma (Germany) a clinical-stage biopharmaceutical company focused on the development of aptamers for the treatment of inflammation and hematological indications closed a $40M Series D financing. Participants include NGN Capital, TVM Capital, Sofinnova Partners, Edmond de Rothschild Investment Partners, Seventure Partners, VC Fonds Technologie Berlin, Dow Venture Capital, Fcp Medical BioHealth-Trends, IBG Beteiligungsgesellschaft Sachsen-Anhalt [...]

Feb

2010

Regado Biosciences, Inc.: Series D $40M

Posted in I - Series D, Q - 4Q09, R - NORTH EAST, X - Anticoagulant, X - Aptamer, XX - NJ

Regado Biosciences (Basking Ridge, NJ) a clinical-stage biopharmaceutical company with an aptamer platform drug-antidote pairing system focused upon the anticoagulant market, closed a $40M Series D financing. Participants include Edmond de Rothschild Investment Partners, Domain Associates, Quaker Bioventures, Aurora Funds and Caxton Advantage Life Sciences Fund.

Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

to top of page...